COVID-19

COVID-19 is a respiratory infection first identified in December 2019 in Wuhan China and rapidly evolved into a global pandemic. The causative agent is an enveloped RNA virus named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). COVID-19 is an infection that can affect multiple organ systems with the respiratory tract being the primary target and can present with a range of clinical severities. The World Health Organization (WHO) declared it a pandemic on 11 March 2020.

Epidemiological Features

Transmission Routes

The primary modes of transmission for COVID-19 include droplet transmission, aerosol transmission, and fomite (surface contact). The most common form of transmission is inhalation of droplets released by infected individuals during coughing sneezing or speaking. Aerosol particles are smaller and can remain suspended in the air for longer periods. Consequently the risk of transmission increases in enclosed poorly ventilated spaces during prolonged exposure.

R0 Value and Variant Effects

The basic reproduction number (R0) for the initial Wuhan strain of SARS-CoV-2 was estimated at 2.2 to 2.6. However the virus has undergone mutations leading to new variants with significantly increased transmissibility:

• Alpha (B.1.1.7): 50% more transmissible.
• Delta (B.1.617.2): R0 estimated between 5 and 8.
• Omicron (BA.1 BA.2 BA.5 and subvariants): R0 estimated above 10. These variants can partially evade the immune system due to mutations in the spike protein.

Risk Groups and Demographic Distribution

Severe forms of COVID-19 are more frequently observed in the following individuals:

• Individuals aged 65 and older
• Those with chronic diseases (diabetes chronic obstructive pulmonary disease heart failure hypertension)
• Patients with immunosuppressed conditions
• Pregnant women
• Healthcare workers

Microbiology and Pathogenesis

SARS-CoV-2 belongs to the Betacoronavirus genus of the Coronaviridae family. Its genetic material consists of a single-stranded positive-sense RNA. The spike (S) glycoprotein on the virus surface binds to ACE2 (Angiotensin Converting Enzyme 2) receptors on human cells to facilitate cellular entry.

Spike Protein and Mutations

The S protein is divided into two subunits:

• S1 subunit: Mediates binding to ACE2.
• S2 subunit: Facilitates fusion of the viral envelope with the host cell membrane.

Mutations are particularly concentrated in the spike protein. For example the Omicron variant has been found to carry over 30 spike mutations. These mutations both increase transmissibility and can reduce vaccine efficacy.

Immune Response and Cytokine Storm

Following viral infection the natural immune response is activated followed by the adaptive immune response. In severe cases an excessive inflammatory response known as a cytokine storm may develop. This condition is associated with pathologically elevated levels of cytokines such as IL-6 TNF-α and IL-1β. This systemic inflammation can lead to complications such as ARDS multiorgan failure and hypercoagulability.

Thrombosis Pathophysiology

SARS-CoV-2 infection triggers thromboembolic events through endothelial dysfunction vasculitis and coagulation disorders. Elevated D-dimer levels are frequently reported in cases of venous thrombosis pulmonary embolism and microthrombosis.

Clinical Manifestations

The incubation period of COVID-19 averages 5–6 days (range: 2–14 days). Clinical symptoms vary widely depending on the severity of infection:

^{Table: Symptoms and Prevalence Rates by Clinical Form}

Common Symptoms

• Fever
• Dry cough
• Loss of taste and smell
• Shortness of breath
• Fatigue
• Muscle pain
• Headache
• Diarrhea and nausea

Long COVID (Post-Acute COVID Syndrome)

In some individuals symptoms persist for more than four weeks after the acute infection. Common symptoms of Long COVID include:

• Memory problems (“brain fog”)
• Prolonged fatigue
• Depression and anxiety
• Sleep disturbances
• Palpitations

Diagnostic Methods

Molecular Diagnosis (RT-PCR)

The most common and reliable method for diagnosing COVID-19 is the RT-PCR test. It detects SARS-CoV-2 RNA in nasal or throat swab samples with sensitivity ranging from 70% to 90%.

Antigen Tests

These provide rapid results but have lower sensitivity compared to molecular tests. They are most effective within the first five days of symptom onset.

Serological Tests

These detect IgM and IgG antibodies produced in response to prior infection. They can also be used to monitor immune response following vaccination.

Imaging

• Chest CT: Typical findings include bilateral peripheral ground-glass opacities.
• Chest X-ray: Used in moderate to severe cases.

Treatment Approaches

Pharmacological Treatment

^{Table: Drugs Used in COVID-19 Treatment and Their Indications}

Supportive Care

• Oxygen support (nasal cannula mask ventilator)
• Fluid and electrolyte balance
• Antibiotics (if secondary infection is present)
• Nutritional support

Vaccination and Prevention Measures

^{Table: Technological Features and Effectiveness of COVID-19 Vaccines}

Immune Escape and Booster Doses

Antibody neutralization is reduced against the Omicron variant and its sublineages therefore booster doses are recommended.

Other Preventive Measures

• Masks
• Hand hygiene
• Physical distancing
• Proper ventilation of indoor spaces

Psychosocial and Economic Impacts of the Pandemic

Societal Psychology

During the COVID-19 pandemic increases in intense anxiety feelings of uncertainty sleep disturbances and post-traumatic stress were observed. Healthcare workers were disproportionately exposed to these stress factors.

Economic Impacts

The pandemic caused a 3.5% decline in global GDP resulting in unemployment reduced production and disruptions in supply chains. The service sector particularly tourism and transportation was severely affected.